Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer
Claudins (CLDNs) are a family of major membrane proteins that form components of tight junctions. In normal tissues, CLDNs seal the intercellular space in the epithelial sheets to regulate tissue permeability, paracellular transport, and signal transduction. Claudin18.2 (CLDN18.2), a member of the C...
Main Authors: | Yohei Kubota, Kohei Shitara |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2024-01-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359231217967 |
Similar Items
-
First-line treatment with zolbetuximab plus CAPOX for ClDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Jianying Lei, et al.
Published: (2024-11-01) -
Heterogeneity of claudin 18.2 expression in metastatic gastric cancer
by: Eugene Choi, et al.
Published: (2024-07-01) -
Claudin18.2: an emerging target for the treatment of gastric cancer
by: WANG Qiangcheng, BAO Jun
Published: (2024-02-01) -
Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma
by: Yufan Huang, et al.
Published: (2023-08-01) -
Dawn of Targeted Therapy Using Claudin18.2 for Gastric Cancer
by: LI Hao, et al.
Published: (2023-10-01)